Cullinan Oncology
Founded 2016 · 128 employees on LinkedIn · 5 known investors
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
Investors · 5
Competitors · 2
by search overlapCullinan Therapeutics8 shared keywordsCullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers. Its focus areas include immune modulation approaches for conditions such as refractory lupus (SLE) and rheumatoid arthritis.
Seeking Alpha4 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Cullinan Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cullinan Oncology do?
- Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
- Who are Cullinan Oncology's investors?
- Cullinan Oncology's investors include LAV, Lilly Asia Ventures, MPM BioImpact, Schooner Capital, Taiho Ventures, LLC.